X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (28475) 28475
Book Review (6913) 6913
Publication (2498) 2498
Book / eBook (503) 503
Book Chapter (115) 115
Magazine Article (98) 98
Conference Proceeding (92) 92
Newspaper Article (57) 57
Newsletter (34) 34
Dissertation (18) 18
Web Resource (10) 10
Trade Publication Article (8) 8
Government Document (7) 7
Data Set (5) 5
Presentation (2) 2
Reference (2) 2
Journal / eJournal (1) 1
Paper (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (26235) 26235
humans (21995) 21995
male (13147) 13147
female (11381) 11381
cardiac & cardiovascular systems (10436) 10436
animals (8657) 8657
middle aged (7401) 7401
risk factors (6539) 6539
aged (6143) 6143
abridged index medicus (5245) 5245
cardiovascular diseases - chemically induced (5201) 5201
adult (5049) 5049
cardiovascular disease (3653) 3653
peripheral vascular disease (3578) 3578
cardiovascular diseases (3322) 3322
rats (3288) 3288
cardiovascular (2798) 2798
risk (2717) 2717
treatment outcome (2692) 2692
pharmacology & pharmacy (2570) 2570
mortality (2567) 2567
time factors (2553) 2553
hypertension (2293) 2293
cardiovascular system (2285) 2285
cardiovascular-disease (2243) 2243
mice (2183) 2183
research (2179) 2179
cardiology (2153) 2153
disease models, animal (2114) 2114
heart (2099) 2099
health aspects (2091) 2091
hemorrhage - chemically induced (1999) 1999
analysis (1971) 1971
drug therapy (1961) 1961
risk assessment (1903) 1903
care and treatment (1890) 1890
aged, 80 and over (1825) 1825
dose-response relationship, drug (1735) 1735
oxidative stress (1716) 1716
myocardial-infarction (1713) 1713
physiology (1704) 1704
medicine, general & internal (1660) 1660
therapy (1619) 1619
cardiovascular diseases - prevention & control (1609) 1609
atherosclerosis (1532) 1532
retrospective studies (1500) 1500
diabetes (1494) 1494
prevention (1476) 1476
disease (1467) 1467
inflammation (1448) 1448
electrocardiography (1447) 1447
medicine & public health (1404) 1404
hematology (1390) 1390
article (1374) 1374
physiological aspects (1368) 1368
surgery (1344) 1344
rodents (1334) 1334
blood pressure - drug effects (1332) 1332
prospective studies (1332) 1332
anticoagulants - adverse effects (1311) 1311
studies (1296) 1296
medicine (1279) 1279
adolescent (1278) 1278
heart failure (1270) 1270
cancer (1261) 1261
respiratory system (1244) 1244
stroke (1243) 1243
follow-up studies (1232) 1232
cardiovascular diseases - epidemiology (1227) 1227
blood pressure (1223) 1223
rats, sprague-dawley (1215) 1215
incidence (1208) 1208
heart diseases (1171) 1171
platelet aggregation inhibitors - adverse effects (1166) 1166
hypertension - chemically induced (1162) 1162
complications and side effects (1157) 1157
toxicology (1154) 1154
drug therapy, combination (1133) 1133
heart attacks (1115) 1115
research article (1044) 1044
proteins (1022) 1022
medical research (1007) 1007
blood-pressure (1006) 1006
randomized controlled trials as topic (981) 981
aspirin (970) 970
expression (956) 956
patients (951) 951
endocrinology & metabolism (933) 933
heart-failure (915) 915
rats, wistar (909) 909
drugs (898) 898
cell biology (895) 895
clinical trials (893) 893
mice, inbred c57bl (887) 887
pregnancy (883) 883
myocardial infarction (877) 877
cardiac patients (873) 873
thrombosis (866) 866
acute myocardial-infarction (861) 861
usage (857) 857
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (423) 423
Collection Dvlpm't (Acquisitions) - Closed Orders (17) 17
Collection Dvlpm't (Acquisitions) - Vendor file (13) 13
Online Resources - Online (9) 9
Scarborough Hospital - General (8) 8
Humber River Regional Hospital - Church Stacks (7) 7
UofT at Scarborough - Stacks (7) 7
Providence Healthcare - Stacks (6) 6
Scarborough Hospital - Birchmount (6) 6
Toronto East General Hospital - Stacks (6) 6
UTL at Downsview - May be requested (6) 6
Humber River Regional Hospital - Finch Stacks (5) 5
Lakeridge Health Sciences - Oshawa (5) 5
St. Michael's Hospital - Stacks (5) 5
Providence Healthcare - Reference (4) 4
Credit Valley Hospital - Stacks (3) 3
Gerstein Science - Circulation Desk (3) 3
Toronto East General Hospital - Reference (3) 3
UofT at Mississauga - Stacks (3) 3
Earth Sciences (Noranda) - Stacks (2) 2
Gerstein Science - Missing (2) 2
Humber River Regional Hospital - Stacks (2) 2
Providence Healthcare - Reserve desk (2) 2
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (2) 2
West Park Healthcare Centre - Stacks (2) 2
Church Stacks (1) 1
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Finch Stacks (1) 1
Gerstein Science - May be requested in 6-10 wks (1) 1
Gerstein Science - Reference (1) 1
Law (Bora Laskin) - Stacks (1) 1
Markham Stouffville Hospital - Stacks (1) 1
Royal Ontario Museum - Stacks (1) 1
Scarborough Hospital - Hospital Department (1) 1
St Josephs Health Centre - Reference (1) 1
St. Michael's Hospital - Circulation Desk (1) 1
Toronto East General Hospital - Pharmacy (1) 1
Trillium Health Centre - Stacks (1) 1
West Park Healthcare Centre - Pharmacy (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (27815) 27815
French (333) 333
German (277) 277
Russian (215) 215
Spanish (183) 183
Italian (98) 98
Polish (78) 78
Japanese (52) 52
Swedish (38) 38
Dutch (37) 37
Norwegian (28) 28
Portuguese (26) 26
Danish (20) 20
Hungarian (18) 18
Czech (17) 17
Chinese (10) 10
Romanian (10) 10
Croatian (9) 9
Finnish (9) 9
Bulgarian (6) 6
Hebrew (6) 6
Turkish (6) 6
Korean (4) 4
Arabic (2) 2
Lithuanian (2) 2
Romansh (1) 1
Serbian (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cardiovascular toxicology, ISSN 1530-7905, 2001
Journal
The New England Journal of Medicine, ISSN 0028-4793, 07/2014, Volume 371, Issue 3, pp. 203 - 212
Adults with vascular disease were treated with a statin to lower LDL cholesterol and were assigned to receive either extended-release niacin plus laropiprant... 
NICOTINIC-ACID | LDL CHOLESTEROL | MEDICINE, GENERAL & INTERNAL | METABOLIC SYNDROME | MYOCARDIAL-INFARCTION | RANDOMIZED-TRIALS | EFFICACY | SAFETY | PLACEBO-CONTROLLED TRIAL | NIACIN/LAROPIPRANT | DYSLIPIDEMIA | Follow-Up Studies | Humans | Middle Aged | Male | Hypercholesterolemia - drug therapy | Indoles - administration & dosage | Infection - chemically induced | Niacin - administration & dosage | Treatment Failure | Musculoskeletal Diseases - chemically induced | Niacin - adverse effects | Cholesterol, LDL - blood | Female | Hypolipidemic Agents - adverse effects | Atherosclerosis - drug therapy | Double-Blind Method | Risk Factors | Indoles - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Hypolipidemic Agents - administration & dosage | Diabetes Mellitus - chemically induced | Aged | Hemorrhage - chemically induced | Delayed-Action Preparations | Drug Combinations | Dose-response relationship (Biochemistry) | Laropiprant | Blood circulation disorders | Care and treatment | Dosage and administration | Niacin | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Heart attacks | Risk groups | Diabetes mellitus | Cardiovascular disease | Low density lipoprotein | Cholesterol | Musculoskeletal system | Vascular diseases | Arteriosclerosis | Vitamin B | Skin | Lipoproteins (high density) | Drug dosages | Statins | Index Medicus | Abridged Index Medicus
Journal Article
JAMA, ISSN 0098-7484, 12/2012, Volume 308, Issue 23, pp. 2497 - 2506
CONTEXT An estimated 10% to 20% of patients cannot tolerate statins or adequate doses to achieve treatment goals. Plasma proprotein convertase subtilisin/kexin... 
LDL CHOLESTEROL | MEDICINE, GENERAL & INTERNAL | THERAPY | EFFICACY | SAFETY | HIGH-RISK | PRIMARY HYPERCHOLESTEROLEMIA | GUIDELINES | CARDIOVASCULAR-DISEASE | EZETIMIBE | Proprotein Convertases - antagonists & inhibitors | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Coronary Disease - epidemiology | Male | Risk | Hypercholesterolemia - drug therapy | Contraindications | Musculoskeletal Pain - chemically induced | Dose-Response Relationship, Drug | Injections, Subcutaneous | Serine Endopeptidases - immunology | Cholesterol, LDL - blood | Female | Muscular Diseases - chemically induced | Syncope - chemically induced | Hip Fractures - chemically induced | Hypercholesterolemia - blood | Coronary Disease - chemically induced | Double-Blind Method | Cholesterol, LDL - drug effects | Anticholesteremic Agents - adverse effects | Proprotein Convertases - immunology | Coronary Disease - prevention & control | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Antibodies, Monoclonal - administration & dosage | Anticholesteremic Agents - administration & dosage | Aged | Proprotein Convertase 9 | Clinical trials | Monoclonal antibodies | Low density lipoprotein | Patients | Index Medicus | Abridged Index Medicus | Medical and Health Sciences | MEDICINE | Medicin och hälsovetenskap | MEDICIN
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2016, Volume 75, Issue 1, pp. 83 - 98.e4
Background Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, has demonstrated efficacy and safety in patients with moderate to severe plaque... 
Dermatology | pooled analysis | phase II studies | phase III studies | psoriasis | secukinumab | long-term safety | Phase III studies | Secukinumab | Long-term safety | Pooled analysis | Psoriasis | Phase II studies | CONTROLLED-TRIAL | CONFIDENCE-INTERVALS | FOLLOW-UP | RISK | long | DERMATOLOGY | LONGITUDINAL ASSESSMENT | CANDIDA-ALBICANS | REGISTRY PSOLAR | DISEASE | DOUBLE-BLIND | HOST-DEFENSE | term safety | Severity of Illness Index | Etanercept - adverse effects | Psoriasis - drug therapy | Etanercept - administration & dosage | Mental Disorders - chemically induced | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Infection - chemically induced | Randomized Controlled Trials as Topic | Clinical Trials, Phase III as Topic | Neoplasms - chemically induced | Interleukin-17 - antagonists & inhibitors | Time Factors | Antibodies, Monoclonal - administration & dosage | Adult | Female | Immunosuppressive Agents - adverse effects | Inflammatory Bowel Diseases - chemically induced | Cardiovascular Diseases - chemically induced | Neutropenia - chemically induced | Immunosuppressive Agents - administration & dosage | Clinical Trials, Phase II as Topic | Medical research | Care and treatment | Interleukins | Clinical trials | Monoclonal antibodies | Medicine, Experimental | Pharmaceutical industry | Consulting services | Index Medicus
Journal Article
by Baigent, Colin and Bhala, N and Emberson, J and Merhi, A and Abramson, S and Arber, N and Baron, J.A and Bombardier, C and Cannon, C and Farkouh, M.E and FitzGerald, G.A and Goss, P and Halls, H and Hawk, E and Hawkey, C and Hennekens, C and Hochberg, M and Holland, L.E and Kearney, P.M and Laine, L and Lanas, A and Lance, P and Laupacis, A and Oates, J and Patrono, C and Schnitzer, T.J and Solomon, S and Tugwell, P and Wilson, K and Wittes, J and Adelowo, O and Aisen, P and Al-Quorain, A and Altman, R and Bakris, G and Baumgartner, H and Bresee, C and Carducci, M and Chang, D.-M and Chou, C.-T and Clegg, D and Cudkowicz, M and Doody, L and Miedany, Y.El and Falandry, C and Farley, J and Ford, L and Garcia-Losa, M and Gonzalez-Ortiz, M and Haghighi, M and Hala, M and Iwama, T and Jajic, Z and Kerr, D and Kim, H.-S and Kohne, C and Koo, B.-K and Martin, B and Meinert, C and Muller, N and Myklebust, G and Neustadt, D and Omdal, R and Ozgocmen, S and Papas, A and Patrignani, P and Pelliccia, F and Roy, V and Schlegelmilch, I and Umar, A and Wahlstrom, O and Wollheim, F and Yocum, S and Zhang, X.Y and Hall, E and McGettigan, P and Midgley, R and Moore, R.A and Philipson, R and Curtis, S and Reicin, A and Bond, J and Moore, A and Essex, M and Fabule, J and Morrison, B and Tive, L and Bhala, N and Davies, K and Emberson, J and Halls, H and Holland, L.E and Kearney, P.M and Merhi, A and Patrono, C and Wilson, K and Yau, F and Coxib Traditional NSAID Trialists and Coxib and traditional NSAID Trialists' (CNT) Collaboration
Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9894, pp. 769 - 779
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 12/2016, Volume 375, Issue 26, pp. 2519 - 2529
BACKGROUND The cardiovascular safety of celecoxib, as compared with nonselective nonsteroidal anti-inflammatory drugs (NSAIDs), remains uncertain. METHODS... 
MEDICINE, GENERAL & INTERNAL | PAIN | METAANALYSIS | OSTEOARTHRITIS | CLINICAL-TRIAL | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | Celecoxib - adverse effects | Naproxen - adverse effects | Ibuprofen - therapeutic use | Humans | Middle Aged | Male | Risk | Celecoxib - therapeutic use | Naproxen - therapeutic use | Cyclooxygenase 2 Inhibitors - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Arthritis - drug therapy | Cyclooxygenase 2 Inhibitors - therapeutic use | Intention to Treat Analysis | Kidney Diseases - chemically induced | Cardiovascular Diseases - mortality | Female | Aged | Cardiovascular Diseases - chemically induced | Ibuprofen - adverse effects | Gastrointestinal Diseases - chemically induced | Care and treatment | Safety and security measures | Naproxen | Ibuprofen | Dosage and administration | Arthritis | Celecoxib | Diagnosis | Cardiovascular diseases | Risk factors | Cardiovascular disease | Side effects | Nonsteroidal anti-inflammatory drugs | Pain management | Myocardial infarction | Fees & charges | Hemorrhage | Pain | Motivation | Analgesics | Safety | Drug dosages | Cerebral infarction | Statistical analysis | Anemia | Committees | FDA approval | Patients | Manuscripts | Nonsteroidal antiinflammatory drugs | Rheumatoid arthritis | Collaboration | Osteoarthritis | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article